Efficacy and feasibility study of docetaxel + capecitabine followed by FEC neoadjuvant therapy for hormone receptor positive and HER2 negative breast cancer
Phase 2
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000013274
- Lead Sponsor
- Department of Surgical Oncology, Osaka City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1 HER2 positive 2 Pregnant or breast feeding 3 Severe infectious disease 4 Active another cancer 5 Hypersensitivity for 5FU, docetaxel or polysolvate 6 Investigator's judgement of inappropriateness for perticipation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pathological CR rate, Feasibility, Overal response rate
- Secondary Outcome Measures
Name Time Method Adverse effects